• (237) 242 003 106
  • welcome@cavie.org
  • FrançaisFrançais
  • EnglishEnglish
    • About
      • History
      • Mission
      • Our Partners
    • Organization
      • Honorary Members
      • Founders
      • Representatives per country
      • Commissions
    • Our Expertise
      • Monitoring
      • Creation of the Monitoring and Economic Intelligence Unit
      • Customised training
      • Due diligence
      • The search for local partnerships
    • Publications
      • Photo Gallery
      • Video gallery
      • African Repository for Business and Competitive Intelligence
    • Join Us
      • Become a Member
      • Become a volunteer
      • Become a Donor
      • Become a certified expert
    • News
      • CAVIE Members News
      • Press
    • About
      • History
      • Mission
      • Our Partners
    • Organization
      • Honorary Members
      • Founders
      • Representatives per country
      • Commissions
    • Our Expertise
      • Monitoring
      • Creation of the Monitoring and Economic Intelligence Unit
      • Customised training
      • Due diligence
      • The search for local partnerships
    • Publications
      • Photo Gallery
      • Video gallery
      • African Repository for Business and Competitive Intelligence
    • Join Us
      • Become a Member
      • Become a volunteer
      • Become a Donor
      • Become a certified expert
    • News
      • CAVIE Members News
      • Press

    Kenya: Bangladeshi Firm to Establish Drugs Plant in Athi River

    • Pharmaceutical Industry
    • 15 December 2021

    [ACCI-CAVIE] Bangladesh’s pharmaceutical market leader, Square Pharmaceuticals, will kick off the production of crucial medicines at its Sh8.4 billion factories in Machakos County early next 2022.

    The multibillion plant built on over six hectares of land at the export processing zones (EPZ) in Athi River will produce malarial and diabetes drugs, among other essential medicine.

    The company management revealed that they will manufacture more than 2 billion tablets and capsules per year, making it the biggest pharmaceutical manufacturing plant in East and Central Africa.

    “Kenya will receive technology and training to manufacture difficult to make anti-malarial, anti-retroviral, anti-hypertensive, anti-psychotic and anti-diabetic drugs,” said the company in a statement Monday 6th December 2021.

    The plant is expected to help minimize the country’s dependency on imported pharmaceutical imports and reduce the cost of drugs, the company further said.

    “Square’s investment to Kenya has come with a potential to transform a pharmaceutical import dependent country to a net exporter of pharmaceuticals soon,” said Tapan Chowdhury, managing director of Square Pharmaceuticals.

    Reduce cost of drugs

    Kenya imports medicines worth Sh65 billion annually, according to official statistics. Apart from lowering the cost of drugs, it is expected to increase access to genuine drugs given the challenge of counterfeits and also generate 700 direct jobs. “We believe that, local pharmaceutical production has a potential to drastically reduce the cost of drugs by 40 per cent and bring about greater access to essential medicines while at the same time promoting the agenda of universal health care,” he said.

    Mr Chowdhury added that they expect phase 1 of the plant to be operational by the start of 2022 at which point they will be able to offer 500 jobs for skilled and unskilled Kenyans.

    “More direct and indirect employment opportunities are projected as we roll out phase 2 and 3 of the project,” stated Mr Chowdhury.

    Manufacturing technology

    The company expects the plant to spur more demand in Kenya of local graduates of industrial pharmacy, engineering and chemistry.

    Square expects to transfer its manufacturing technology from its parent company in Bangladesh to Kenya.

    “This facility shall facilitate pharmaceuticals manufacturing capacity building for Kenya, which shall reduce Kenya’s medicine import dependency,” said the company.

    Square Pharmaceuticals is accredited by the US Food and Drug Administration (FDA), Medicine and Health Products Regulatory Agency (MHRA) UK, Therapeutic Goods Administration (TGA) Australia and the South African Health Products Regulatory Authority (SAHPRA) as well as the Kenyan Pharmacy and Poison Board (PPB).

    With a market cap of $3 billion (Sh336 billion), Square Pharmaceuticals is the leader of Bangladesh pharmaceuticals market and the flagship company of Bangladesh conglomerate Square Group, which comprises of 27 companies and over 60,000 employees operating across a number sectors including textiles, IT, consumer product, toiletries, banking, insurance, media and agro-processing.

    In 2020-2021 financial period the Square Pharmaceuticals turnover was close to $700 million from supply of medicines to 45 countries.

    By Victor Raballa

    Share

    Newsletter

    Shortcodes Ultimate

    Texte du bouton

    Category

    • Aeronautics(36)
    • Automobile(35)
    • Banking(34)
    • CAVIE Members News(35)
    • Defense(43)
    • Education(34)
    • Energy(41)
    • Food and Agriculture(47)
    • Insurance(31)
    • News(31)
    • Non classé(19)
    • Pharmaceutical Industry(43)
    • Press(173)
    • Public Works(32)
    • Raw Materials(34)
    • Sectors(0)
    • Telecommunications(39)

    recent post

    BNP Paribas Fortis : Decrypting African Economies in 2023 – Guest Speaker : Guy GWETH
    15 May 2023
    Morocco’s international promise : The time for reward has come, By Dr Ghizlane SALAM
    13 March 2023
    Huawei to Invest Over $300 Million in Africa’s Data Center & Cybersecurity Industry
    10 March 2023
    Airtel Africa, UNICEF commit $57m to digital education
    10 March 2023

    Direct Links

    • A center for 54 States
    • 12 Sectors under surveillance
    • Become a certified expert
    • Become a Member
    • Become a Donor

    Gallery

    VIMAIII
    JAIE2019 (8)
    JAIE2019 (7)
    JAIE2019 (6)
    JAIE2019 (5)
    JAIE2019 (4)
    SIEGE CAVIE
    B.P : 35605 Yaoundé Cameroun
    SIEGE CAVIE UE
    Rond-point Schuman 2-4, Étage 6, 1040 Bruxelles
    (237) 242 003 106
    (237) 243 744 462
    +32(0)2 403 36 56
    welcome[a]cavie.org
    contact[a]cavie.org
    cavie.europe[a]cavie.org
    COPYRIGHT © 2018. | PRIVACY POLICY | ALL RIGHTS RESERVED